Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy

Cancer immunotherapies, such as checkpoint blockade of programmed cell death protein-1 (PD-1), represents a breakthrough in cancer treatment, resulting in unprecedented results in terms of overall and progression-free survival. Discovery and development of novel anti PD-1 inhibitors remains a field...

Descripción completa

Detalles Bibliográficos
Autores principales: Issafras, Hassan, Fan, Shilong, Tseng, Chi-Ling, Cheng, Yunchih, Lin, Peihua, Xiao, Lisa, Huang, Yun-Ju, Tu, Chih-Hsiang, Hsiao, Ya-Chin, Li, Min, Chen, Yen-Hsiao, Ho, Chien-Hsin, Li, Ou, Wang, Yanling, Chen, Sandra, Ji, Zhenyu, Zhang, Eric, Mao, Yi-Ting, Liu, Eugene, Yang, Shumin, Jiang, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719770/
https://www.ncbi.nlm.nih.gov/pubmed/34972111
http://dx.doi.org/10.1371/journal.pone.0257972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719770/
https://www.ncbi.nlm.nih.gov/pubmed/34972111
http://dx.doi.org/10.1371/journal.pone.0257972

Ejemplares similares